---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Pharmacodynamics"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Pharmacodynamics. Topics: Maximal TYK2 inhibition over 24 hours with twice-daily dosing, Preclinical inhibition of STAT phosphorylation and interferon-gamma production, Blood biomarkers of TYK2 inhibition in healthy participants, Blood and skin biomarkers in the STRIDE phase 2 study, and 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Maximal TYK2 inhibition over 24 hours with twice-daily dosing

> “Indeed, preclinical and phase 1 studies demonstrated that envudeucitinib twice daily achieves maximal TYK2 target inhibition (90% inhibitory concentration [IC90]) at clinically relevant doses over 24 h”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “Envu demonstrated a robust and predictable PK/PD relationship in Phase 1 studies, enabling the identification of a dose level that achieved maximal TYK2 inhibition for 24 hours a day to take into Phase 2 clinical trials.”
> “We define maximal inhibition as reaching the plateau of biological inhibition in the assay readout with no further impact seen with higher drug concentrations.”
> “At the 40 mg BID dose, maximal TYK2 inhibition was confirmed in healthy volunteer and PsO patient blood samples by RNA-seq analysis, and a return to non-lesional baseline levels of TYK2 pathway (including IFN signature, IL-23, IL-17) and PsO-relevant disease biomarkers was confirmed in PsO patient skin biopsies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.6.2-2"></a>

### Preclinical inhibition of STAT phosphorylation and interferon-gamma production

> “Additionally, ESK‐001 significantly inhibited STAT phosphorylation and downstream IFNγ production stimulated by IL‐12, IL‐23, and IFNα in human whole blood and peripheral blood mononuclear cells in a concentration‐dependent manner.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.2-3"></a>

### Blood biomarkers of TYK2 inhibition in healthy participants

> “ESK‐001 inhibited the downstream TYK2 pathway as shown by inhibition of pSTAT1 expression.”
> “Transcriptomic analysis of unstimulated whole blood samples confirmed dose‐dependent inhibition of Type I IFN‐induced genes and SIGLEC1, a novel TYK2‐responsive biomarker.”
> “By correlating PK exposure data with PD readouts, a strong PK/PD relationship was demonstrated.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “SIGLEC1 expression is a novel biomarker to assess TYK2 target inhibition”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.2-4"></a>

### Blood and skin biomarkers in the STRIDE phase 2 study

> “STRIDE Ph2 Blood RNA-seq of Trough Drug Levels Shows Dose-Dependent Type I IFN Gene Signature Inhibition, Findings Consistent with Ph1”
> “Phase 2 Blood RNA-seq of Novel TYK2-Responsive Marker, SIGLEC1, Confirms Full Target Inhibition”
> “Lesional Skin Levels of Key Cytokines & Disease Related Biomarkers Return to Non-lesional Levels”
> “ESK-001 maximally inhibits TYK2, demonstrated by biomarkers in blood and confirmed in skin”
> “ESK-001 returned key psoriasis disease biomarkers in lesional skin to baseline/non-lesional levels and improved histological outcomes”
> “Modulation of TYK2 pathway and disease-related biomarkers closely mirrored clinical outcomes.”

Source: [Tilley et al. (2024)](https://www.alumis.com/file.cfm/18/docs/final_eadv_2024_biomarker_oral_presentation.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Circulating IL-23, IL-17A, and IL-22 in the STRIDE phase 2 study

> “Proteomic analysis showed reduced expression of blood biomarkers IL-23 and IL-17A after 12 weeks of ESK-001 treatment.”
> “ESK-001 40 mg QD and 40 mg BID reduced circulating IL-23 protein plasma levels by a median of nearly 100%.”
> “ESK-001 40 mg QD and 40 mg BID reduced circulating IL-22 levels by 0.99 and 2.1 log2 foldchange, respectively.”
> “Patients with high intrinsic IL-23 pathway expression were most likely to achieve high and rapid PASI75 response in the dose group with maximal target engagement (ESK-001 40 mg BID).”

Source: [Narayan et al. (2025)](https://www.alumis.com/file.cfm/18/docs/20250129_aad2025_pstr_biomarkers_final.pdf)

<a id="topic-2.1.2.6.2-6"></a>

### Skin tape-strip transcriptomics and proteomics in a STRIDE subgroup

> “Placebo (N=10), envudeucitinib 40 mg once daily (QD) (N=10), and envudeucitinib 40 mg twice daily (BID) (N=8)”
> “Greatest molecular suppression was observed in the envudeucitinib 40 mg BID group, paralleling dose-dependent improvements in clinical scores.”
> “In moderate-to-severe plaque PsO, envudeucitinib achieved robust suppression of pathogenic IL-23 and IFN-related pathways at transcriptomic and proteomic levels, underscoring its potential as an effective therapeutic strategy.”
> “IL-36A expression was inhibited to non-lesional levels in skin punch biopsies of patients after envudeucitinib treatment, primarily in supraspinous keratinocyte layer”

Source: [Tilley et al. (2026)](https://www.alumis.com/file.cfm/613/docs/aad2026_biomarkers_final.pdf)

> “Both 40 mg QD and BID groups showed downregulation of immune gene expression, with significant decreases in Interferon-, Th1-, and Th17-related markers”
> “Gene set variation analysis of tape strip RNA-seq revealed greater molecular suppression in the 40 mg BID group at Week 12”
> “Clinical improvements were strongly correlated with transcript reductions of IFNG, IL22, IL17A, and key cytokines”

Source: [Zhou et al. (2025)](https://www.alumis.com/file.cfm/613/docs/isds_poster_final.pdf)

<a id="topic-2.1.2.6.2-7"></a>

### Spatial transcriptomics of skin biopsies in a STRIDE subgroup

> “Subjects selected based on availability of baseline and week 12 biopsies: placebo (n=4) and envudeucitinib 40 mg twice daily (BID) (highest dose, n=5) are presented.”
> “In the Phase 2 STRIDE study, spatial transcriptomic analysis demonstrated that envudeucitinib robustly inhibited pathogenic IL-23 and IL-17 pathway signaling in PsO-relevant skin cell types, including keratinocytes and myeloid/T cell subsets”
> “Expression of CCL19, CCR7, and IL4I1 return to non-lesional levels after envudeucitinib treatment”
> “CCR7+IL4I1+ dendritic cells are primary producers of IL-23 in PsO.”

Source: [Narayan et al. (2026a)](https://www.alumis.com/file.cfm/613/docs/20260427_sid2026_pstr_biomarkers_final.pdf)

> “Subjects dosed with envudeucitinib enriched in non‐inflammatory supraspinous keratinocytes compared to subjects dosed with placebo.”
> “Envudeucitinib suppressed a pathologic inflammatory supraspinous keratinocyte state associated with aberrant differentiation in psoriasis skin.”

Source: [Narayan et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/eadv2026_biomarker-data-poster.pdf)

<a id="topic-2.1.2.6.2-8"></a>

### Trough coverage of the IC90 and exposure-response in the STRIDE open-label extension

> “The 40-mg BID regimen achieved continuous IC90 coverage at trough over 24 hours, surpassing the in vitro human whole blood pSTAT-IFNα IC90 (144 ng/mL) and ensuring sustained TYK2 inhibition for optimal target engagement.”
> “Higher envudeucitinib exposures were associated with improved PASI outcomes, with patients achieving PASI-90 and PASI-100 showing greater mean exposures compared to those achieving PASI-75.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-2.1.2.6.2-9"></a>

### Interferon-pathway target engagement in the LUMUS phase 2b lupus trial

> “Pharmacodynamic data from LUMUS confirmed robust dose-dependent interferon-pathway target engagement, with maximal suppression at the highest dose, 40 mg twice daily.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

<a id="topic-2.1.2.6.2-10"></a>

### Cardiac repolarization: structural hypothesis

> “Moreover, the presence of a cyclopropyl carboxamide group on envudeucitinib is hypothesized to reduce human ether-a-go-go-related gene (hERG) and cardiac repolarization-associated safety concerns”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
